Free Trial
NASDAQ:TECH

Bio-Techne (TECH) Stock Price, News & Analysis

Bio-Techne logo
$56.22 -0.57 (-1.00%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$55.90 -0.32 (-0.58%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bio-Techne Stock (NASDAQ:TECH)

Key Stats

Today's Range
$56.02
$57.37
50-Day Range
$49.30
$58.78
52-Week Range
$46.01
$80.95
Volume
1.81 million shs
Average Volume
2.18 million shs
Market Capitalization
$8.81 billion
P/E Ratio
122.22
Dividend Yield
0.57%
Price Target
$69.42
Consensus Rating
Moderate Buy

Company Overview

Bio-Techne Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

TECH MarketRank™: 

Bio-Techne scored higher than 97% of companies evaluated by MarketBeat, and ranked 44th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Techne has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 7 buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bio-Techne has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bio-Techne's stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Techne are expected to grow by 17.96% in the coming year, from $1.67 to $1.97 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Techne is 122.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.69.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Techne is 122.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.80.

  • Price to Earnings Growth Ratio

    Bio-Techne has a PEG Ratio of 3.62. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bio-Techne has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Bio-Techne's valuation and earnings.
  • Percentage of Shares Shorted

    4.21% of the float of Bio-Techne has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Techne has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Techne has recently decreased by 2.91%, indicating that investor sentiment is improving.
  • Dividend Yield

    Bio-Techne has a dividend yield of 0.56%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Bio-Techne does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Bio-Techne is 69.57%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.24% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

  • Read more about Bio-Techne's dividend.
  • Percentage of Shares Shorted

    4.21% of the float of Bio-Techne has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Techne has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Techne has recently decreased by 2.91%, indicating that investor sentiment is improving.
  • News Sentiment

    Bio-Techne has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 25 news articles for Bio-Techne this week, compared to 15 articles on an average week.
  • Search Interest

    Only 3 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Techne insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of Bio-Techne is held by insiders.

  • Percentage Held by Institutions

    98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Techne's insider trading history.
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TECH Stock News Headlines

Bio-Techne to Present at Upcoming Investor Conferences
Bio-Techne (NASDAQ:TECH) Upgraded at Citigroup
Tax Drain Deadline: Protect Your Wealth Before September 15th
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
6 Analysts Have This To Say About Bio-Techne
Bio-Techne Stock: Analyst Estimates & Ratings
See More Headlines

TECH Stock Analysis - Frequently Asked Questions

Bio-Techne's stock was trading at $72.03 on January 1st, 2025. Since then, TECH stock has decreased by 21.9% and is now trading at $56.22.

Bio-Techne Corp (NASDAQ:TECH) posted its quarterly earnings results on Wednesday, August, 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.03. The company's revenue for the quarter was up 3.6% compared to the same quarter last year.
Read the conference call transcript
.

Bio-Techne shares split on Wednesday, November 30th 2022.The 4-1 split was announced on Tuesday, November 1st 2022. The newly created shares were distributed to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Bio-Techne's Board of Directors initiated a stock buyback plan on Wednesday, May 7th 2025, which authorizes the company to buy back $500,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 6.5% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's leadership believes its shares are undervalued.

Bio-Techne subsidiaries include these companies: MoGen Biotechnologies, Exosome Diagnostics, Quad Technologies, Advanced Cell Diagnostics, Space Import-Export Srl, Zephyrus Biosciences, Cliniqa, and others.

Top institutional investors of Bio-Techne include State Street Corp (3.74%), Geode Capital Management LLC (2.59%), Invesco Ltd. (2.34%) and Ameriprise Financial Inc. (2.19%). Insiders that own company stock include Roeland Nusse, Kim Kelderman, Brenda S Furlow and Amy E Herr.
View institutional ownership trends
.

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Techne investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

Record date for 5/30 Dividend
5/19/2025
Ex-Dividend for 5/30 Dividend
5/19/2025
Dividend Payable
5/30/2025
Last Earnings
8/06/2025
Record date for 8/29 Dividend
8/18/2025
Ex-Dividend for 8/29 Dividend
8/18/2025
Today
8/28/2025
Dividend Payable
8/29/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:TECH
CIK
842023
Employees
3,100
Year Founded
1981

Price Target and Rating

High Price Target
$90.00
Low Price Target
$59.00
Potential Upside/Downside
+23.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.46
Trailing P/E Ratio
122.22
Forward P/E Ratio
33.66
P/E Growth
3.62
Net Income
$73.40 million
Net Margins
6.02%
Pretax Margin
8.07%
Return on Equity
13.43%
Return on Assets
10.32%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
3.46
Quick Ratio
2.38

Sales & Book Value

Annual Sales
$1.22 billion
Price / Sales
7.23
Cash Flow
$2.42 per share
Price / Cash Flow
23.23
Book Value
$12.24 per share
Price / Book
4.59

Miscellaneous

Outstanding Shares
156,770,000
Free Float
150,653,000
Market Cap
$8.81 billion
Optionable
Optionable
Beta
1.40

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:TECH) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners